{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:38:35Z","timestamp":1792802315071,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:00Z","timestamp":1792800000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The main purpose of this study is to demonstrate the decrease in headache severity, pain duration and the number of painful days in a month after repetitive GON blockade applied with local anesthetic in menstrual migraine patients compared to the placebo group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized, double-blind, placebo-controlled study included 48 menstrual migraine patients. 24 patients received medication (0.5% bupivacaine) and 24 received placebo (saline) GON blockade twice a month for three months. Baseline data (month 0) relied on retrospective recall, whereas post-treatment data (months 3 and 6) were collected prospectively using a paper-based headache diary. The primary outcome was the change in headache severity (VAS score). Secondary outcomes included attack frequency, duration, number of headache days, analgesic use, and MIDAS scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics were similar between groups. At month 3, the active group showed a significantly greater reduction in the primary outcome, VAS scores, compared to the placebo group (decreasing from 8.75\u2009\u00b1\u20090.67 to 3.80\u2009\u00b1\u20093.18 vs. 8.71\u2009\u00b1\u20091.04 to 7.16\u2009\u00b1\u20091.31;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Significant reductions were also observed in secondary outcomes including monthly attack frequency (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), mean attack duration (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), number of headache days (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), MIDAS scores (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), and analgesic use (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). Mild, transient injection-site tenderness was the only reported side effect. The clinical improvements were maintained at the 6th month, suggesting a potential sustained benefit, though natural history or late placebo responses cannot be fully excluded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Repetitive perimenstrual GON blockade may be an effective short-term prophylaxis for MM. However, the observed effects on the subjective primary endpoint (VAS) may be partially attributable to imperfect blinding, and all secondary outcomes are exploratory. Further studies are needed to confirm these findings and exclude natural history or placebo responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT07576309. Registered on 08 May 2026. Retrospectively registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-05238-0","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:13:48Z","timestamp":1787015628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perimenstrual repetitive greater occipital nerve blockade for menstrual migraine: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Okan","family":"Ak\u015fahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazl\u0131 Gamze","family":"B\u00fclb\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Fatih","family":"\u00d6zda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"8","key":"5238_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/head.12150","volume":"53","author":"DC Buse","year":"2013","unstructured":"Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, Serrano D, Lipton RB. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American migraine prevalence and prevention (AMPP) study. Headache. 2013;53(8):1278\u201399.","journal-title":"Headache"},{"issue":"3","key":"5238_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1177\/0333102417739584","volume":"39","author":"A Labastida-Ram\u00edrez","year":"2017","unstructured":"Labastida-Ram\u00edrez A, Rubio-Beltran E, Villalon CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. Cephalalgia. 2017;39(3):435\u201344.","journal-title":"Cephalalgia"},{"key":"5238_CR3","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018;38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202 .","DOI":"10.1177\/0333102417738202"},{"issue":"5","key":"5238_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1756285609335537","volume":"2","author":"EA MacGregor","year":"2009","unstructured":"MacGregor EA. Menstrual migraine: therapeutic approaches. Ther Adv Neurol Disord. 2009;2(5):327\u201336.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"5238_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11916-007-0195-3","volume":"11","author":"A Ashkenazi","year":"2007","unstructured":"Ashkenazi A, Levin M. Greater occipital nerve block for migraine and other headaches: is it useful? Curr Pain Headache Rep. 2007;11(3):231\u20135.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"5238_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12883-025-04070-2","volume":"25","author":"G Cetin","year":"2025","unstructured":"Cetin G, Totuk O, Cetin OE, Demir S, Sahin S. Evaluation of the effectiveness of greater occipital nerve blockade in menstrual migraine. BMC Neurol. 2025;25(1):62.","journal-title":"BMC Neurol"},{"issue":"2","key":"5238_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/0894439305281503","volume":"24","author":"MP Couper","year":"2006","unstructured":"Couper MP, Tourangeau R, Conrad FG, Singer E. Evaluating the effectiveness of visual analog scales: A web experiment. Social Sci Comput Rev. 2006;24(2):227\u201345.","journal-title":"Social Sci Comput Rev"},{"issue":"3","key":"5238_CR8","first-page":"e088","volume":"2","author":"DA Delgado","year":"2018","unstructured":"Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev. 2018;2(3):e088.","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"5238_CR9","doi-asserted-by":"crossref","unstructured":"Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88(1):41\u201352","DOI":"10.1016\/S0304-3959(00)00305-5"},{"key":"5238_CR10","doi-asserted-by":"crossref","unstructured":"Seo JG. Menstrual Migraine: A Review of Current Research and Clinical Challenges. Headache Pain Res. 2024;25(1):16\u201323.","DOI":"10.62087\/hpr.2024.0004"},{"issue":"7","key":"5238_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10194-012-0475-0","volume":"13","author":"N Karl\u0131","year":"2012","unstructured":"Karl\u0131 N, Baykan B, Erta\u015f M, Zarifoglu M, Siva A. Impact of sex hormonal changes on tension-type headache and migraine: a population-based survey in 2,600 women. J Headache Pain. 2012;13(7):557\u201365.","journal-title":"J Headache Pain"},{"issue":"1","key":"5238_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1783\/147118907779399684","volume":"33","author":"EA MacGregor","year":"2007","unstructured":"MacGregor EA. Menstrual migraine: a clinical review. J Fam Plann Reprod Health Care. 2007;33(1):36\u201347.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"5238_CR13","doi-asserted-by":"crossref","unstructured":"Pavlovi\u0107 JM, Allshouse AA, Santoro NF, Crawford SL, Thurston RC, et al. Sex hormones in women with and without migraine. Neurology. 2016;87(1):49\u201356.","DOI":"10.1212\/WNL.0000000000002798"},{"issue":"2","key":"5238_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev. 2017;97(2):553\u2013622.","journal-title":"Physiol Rev"},{"issue":"1","key":"5238_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/neurolint14010016","volume":"14","author":"A Abbas","year":"2022","unstructured":"Abbas A, Moustafa R, Shalash A, Harun M, Amin R. Serum CGRP changes following ultrasound-guided bilateral greater occipital nerve block. Neurol Int. 2022;14(1):199\u2013206.","journal-title":"Neurol Int"},{"issue":"1","key":"5238_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1476-5381.2011.01391.x","volume":"164","author":"DP Roberson","year":"2011","unstructured":"Roberson DP, Binshtok AM, Blasl F, Bean BP, Woolf CJ. Targeting of sodium channel blockers into nociceptors to produce long-duration analgesia: a systematic study and review. Br J Pharmacol. 2011;164(1):48\u201358.","journal-title":"Br J Pharmacol"},{"issue":"Pt 7","key":"5238_CR17","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/brain\/awf166","volume":"125","author":"T Bartsch","year":"2002","unstructured":"Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain. 2002;125(Pt 7):1496\u2013509.","journal-title":"Brain"},{"issue":"2","key":"5238_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.2001.00166.x","volume":"21","author":"EJ Piovesan","year":"2001","unstructured":"Piovesan EJ, Kowacs PA, Tatsui CE, Lange MC, Ribas LC. Referred pain after painful stimulation of the greater occipital nerve in humans: evidence of convergence of cervical afferences on trigeminal nuclei. Cephalalgia. 2001;21(2):107\u20139.","journal-title":"Cephalalgia"},{"key":"5238_CR19","doi-asserted-by":"crossref","unstructured":"Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options: Review. Headache. 2017;57(2):194\u2013208.","DOI":"10.1111\/head.12978"},{"issue":"7","key":"5238_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1177\/0333102418821669","volume":"39","author":"LE Inan","year":"2019","unstructured":"Inan LE, Inan N, Unal-Art\u0131k HA, Atac C, Babaoglu G. Greater occipital nerve block in migraine prophylaxis: narrative review. Cephalalgia. 2019;39(7):908\u201320.","journal-title":"Cephalalgia"},{"key":"5238_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.clineuro.2017.12.026","volume":"165","author":"H Zhang","year":"2018","unstructured":"Zhang H, Yang X, Lin Y, Chen L, Ye H. The efficacy of greater occipital nerve block for the treatment of migraine: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2018;165:129\u201333.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"5238_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12883-024-03834-6","volume":"24","author":"MS Mustafa","year":"2024","unstructured":"Mustafa MS, Amin S, Kumar A, Shafique MA, Zaidi SMF, et al. Assessing the effectiveness of greater occipital nerve block in chronic migraine: a systematic review and meta-analysis. BMC Neurol. 2024;24(1):330.","journal-title":"BMC Neurol"},{"issue":"7","key":"5238_CR23","first-page":"735","volume":"11","author":"HC Diener","year":"2010","unstructured":"Diener HC. Placebo effects in treating migraine and other headaches. Curr Opin Investig Drugs. 2010;11(7):735\u20139.","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"5238_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/ane.12716","volume":"136","author":"HL Gul","year":"2017","unstructured":"Gul HL, Ozon AO, Karadas O, Koc G, Inan LE. The efficacy of greater occipital nerve blockade in chronic migraine: A placebo-controlled study. Acta Neurol Scand. 2017;136(2):138\u201344.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"5238_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","volume":"19","author":"TJ Steiner","year":"2018","unstructured":"Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: Will health politicians now take notice? J Headache Pain. 2018;19(1):17.","journal-title":"J Headache Pain"},{"key":"5238_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s10194-015-0503-y","volume":"16","author":"JM Pavlovic","year":"2015","unstructured":"Pavlovic JM, Stewart WF, Bruce CA, Gorman JA, Sun H, Buse DC, Lipton RB. Burden of migraine related to menses: Results from the AMPP study. J Headache Pain. 2015;16:24.","journal-title":"J Headache Pain"},{"issue":"10","key":"5238_CR27","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/j.1526-4610.2012.02270.x","volume":"52","author":"G Lambru","year":"2012","unstructured":"Lambru G, Lagrata S, Matharu MS. Cutaneous atrophy and alopecia after greater occipital nerve injection using triamcinolone. Headache. 2012;52(10):1596\u20139.","journal-title":"Headache"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05238-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:05:23Z","timestamp":1792800323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05238-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5238"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05238-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Istanbul Medipol University (File No: E66291034-202.3.02-5953, Date:26.09.2024). All methods were performed in accordance with the Declaration of Helsinki, and written informed consent was obtained from the patients after explaining the purpose of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"668"}}